Galecto, Inc. (GLTO) fair value analysis
Nasdaq · Updated 2026-10-19
GLTO price how computed
Valuation status
No fair-value estimate yetGLTO has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for GLTO yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $18.44
- Sector
- Healthcare
- 12-month range
- $4.95–$34.14
- From 52-week high
- -46.0%
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Galecto, Inc. is a biotechnology company focused on the development and commercialization of therapeutics for fibrosis and other serious diseases. The company is headquartered in the United States and operates in the Healthcare sector.
Derived indicators how computed
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- 50-day average
- $25.44
- 200-day average
- $25.69
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
What our data shows for GLTO
- Shares are trading in the middle of their 12-month price range of $4.95–$34.14.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- GLTO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the GLTO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is GLTO stock undervalued?
TickrTrends has no fair-value estimate for GLTO yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is GLTO's TickrTrends verdict?
GLTO is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
Is GLTO overbought or oversold?
TickrTrends does not currently publish an RSI signal for GLTO.